Aimaz Afrough, MD
Aimaz Afrough, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center. She specializes in multiple myeloma and other plasma cell dyscrasias, developing cellular therapy such as CAR T-cells with or without transplant, and immunotherapy.
Dr. Afrough earned her medical degree at Tabriz University of Medical Sciences in Iran and completed a residency in internal medicine at St. Agnes Hospital in Baltimore. She received advanced training through a hematology and oncology fellowship at Baylor College of Medicine and a stem cell transplantation and cellular therapy fellowship at the University of Texas MD Anderson Cancer Center.
Certified by the American Board of Internal Medicine in medical oncology and in hematology, she joined the UT Southwestern faculty in 2021.
Dr. Afrough’s clinical research is focused on improving the therapy and outcome of patients with plasma cell disorders. She is particularly interested in developing novel therapeutic approaches, including adoptive cell therapy, to improve the safety and efficacy of therapies in patients with these disorders. She has published numerous academic articles and delivered multiple presentations.
She is a member of several professional associations, including the American Society of Clinical Oncology, the American Society of Hematology, the American Society for Transplantation and Cellular Therapy, and the International Myeloma Society.
In 2019, Dr. Afrough earned the Cancer Prevention and Research Institute of Texas (CPRIT) Training Award from the Baylor College of Medicine Comprehensive Cancer Training Program.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AbbviDate added:10/19/2022Date updated:11/10/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ClonoSEQDate added:10/04/2023Date updated:11/10/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:JanssenDate added:10/15/2024Date updated:11/10/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Regeneron PharmaceuticalsDate added:10/15/2024Date updated:11/10/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:K36 Therapeutics, IncDate added:10/15/2024Date updated:11/10/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:JanssenDate added:10/15/2024Date updated:11/10/2025Relationship end date:10/10/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:KaryopharmDate added:10/15/2024Date updated:11/10/2025Relationship end date:12/08/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:SanofiDate added:10/15/2024Date updated:11/10/2025Relationship end date:06/27/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BMSDate added:10/15/2024Date updated:11/10/2025Relationship end date:01/17/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:PfizerDate added:10/15/2024Date updated:11/10/2025Relationship end date:09/28/2024
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.

Facebook
X
LinkedIn
Forward